Skip to main content

Table 1 M3 cohort demographics

From: Post-intensive care syndrome after a critical COVID-19: cohort study from a Belgian follow-up clinic

Data COVID-19 ICU cohort
n = 92
ICU patients deceased at hospital
n = 31
M3 cohort
n = 32
Age, years 65 [54–71] 70 [60–79] 62 [49–68]
Male, n (%) 63 (68.5) 23 (74.2) 23 (72)
Weight, kg 93 [80–101] 93 [80–105] 99 [86–105]
Height, cm 173 [165–180] 172 [167–180] 173 [164–180]
BMI, kg/m2 30.9 [27–34] 31.1 [26.1–35] 31.5 [30–34.8]
Comorbidities
 Diabetes 37 (40.2) 15 (48.4) 20 (62.5)
 Hypertension 54 (58.7) 21 (67.7) 17 (53.1)
 Cardiaca 35 (38) 16 (51.6) 10 (31.2)
 Respiratoryb 16 (17.4) 8 (25.8) 4 (12.5)
 Chronic kidney disease 18 (19.6) 12 (38.7) 2 (6.2)
 Immunosuppression 5 (5.4) 3 (9.7) 1 (3.1)
 SOFA at admission 6 [3–8] 7 [5–8] 7 [4–8]
 SAPS II 36 [28–47] 42 [33–54] 37.5 [30.5–44]
Mechanical ventilation, n (%) 71 (77.2) 28 (90.3) 30 (93.7)
Duration of mechanical ventilation, days 17 [11–26] 13 [6–23] 21 [12–29]
PaO2/FiO2 at admission 97.5 [74.1–131]
Worse PaO2/FiO2 71.1 [62.1–81.1]
Vasopressive support, n (%) 56 (60.9) 24 (77.4) 27 (84.4)
Duration of norepinephrine administration, days 17 [11–26] 4 [1–13] 5 [2–10.5]
Peak creatinine > upper reference value, n (%) 23 (71.8)
Peak creatinine, mg/dL 1.7 [1–4.1]
Worse eGFR (MDRD), ml/min/1.73 m2 40.7 [14.4–65.8]
Renal replacement therapy, n (%) 18 (19.6) 10 (32.3) 5 (15.6)
Extracorporeal membrane oxygenation, n (%) 3 (3.3) 3 (9.7) 0
Peak C-reactive protein, mg/L 306.4 [253.1–363.2]
ICU LOS, days 16 [7–28] 13 [7–23] 23 [15–39]
Hospital LOS, days 19 [12–28] 14.4 [9–24] 40 [29–52]
Hospital mortality, n (%) 31 (33.7) 31 (100)
Destination at hospital discharge
 Home, n (%) 15 (46.9)
 Rehabilitation facility, n (%) 17 (53.1)
Rehabilitation center LOS, days 30 [20–40]
  1. BMI body mass index, ICU intensive care unit, LOS length of stay, SAPS II simplified acute physiology score, SOFA sequential organ failure assessment
  2. aIschemic heart disease, valvular disease, cardiomyopathies, and chronic heart disease
  3. bAsthma, chronic obstructive pulmonary disease and interstitial lung diseases